Golgi expands marketing
Nicosia – Golgi Pharmaceuticals Ltd is strengthening its collaboration with London-based ReGen Therapeutics. The Cypriot firm will produce and package Colostrinin tablets, and expand distribution to Greece and other Balkan countries. The proline-rich polypeptide complex is derived from mammalian colostrum. The compound and peptides it contains could have potential treating neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and Amyotrophic Lateral Sclerosis according to clinical studies conducted in Poland in 2002. In 2008, Cyprus was the first EU state to allow sales of Colostrinin.